Sleep Disorders Clinical Trial
Official title:
Effect of High Rebound Mattress Toppers on Sleep and Sleep-Related Symptoms
NCT number | NCT03055156 |
Other study ID # | IRB-34797 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | October 2015 |
Est. completion date | October 19, 2019 |
Verified date | October 2020 |
Source | Stanford University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is to evaluate effects of high rebound mattress toppers (i.e., airweave®) on sleep and sleep-related symptoms. The study will compare effects of use of high rebound mattress toppers versus use of low rebound mattress toppers on sleep and sleep related symptoms and core body temperature during diagnostic sleep studies.
Status | Completed |
Enrollment | 558 |
Est. completion date | October 19, 2019 |
Est. primary completion date | October 19, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Adults Age 18-65 who are scheduled for a diagnostic sleep study at the Stanford Sleep Clinic for sleep disorders (including but not limited to, insomnia, Sleep Apnea or other sleep disorder symptoms). Exclusion Criteria: - Individuals with a history of having difficulty swallowing food or large capsules. We will not be able to enroll individuals with any known or suspected obstructive disease of the gastrointestinal tract including, but not limited to esophageal stricture, diverticulosis and inflammatory bowel disease (IBD), peptic ulcer disease, Crohn's disease, ulcerative colitis, previous gastrointestinal surgery. - Individuals who are pregnant. - Individuals who are unable to provide informed consent (i.e. decisionally impaired). |
Country | Name | City | State |
---|---|---|---|
United States | Stanford Sleep Research Center | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
Stanford University | AIRWEAVE PTE. LTD. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total Sleep Time | Overnight study visit (up to approximately 10hrs) | ||
Primary | Sleep Efficiency Assessed by Polysomnography (PSG) | Sleep efficiency is total sleep time divided by time in bed. All data were collected through the PSG data that were retrieved from the patients' medical records after completion of the recordings and analysis by the sleep technologists. | Overnight study visit (up to approximately 10hrs) | |
Primary | Sleep Latency Assessed by PSG | The amount of time from lights off to falling asleep. | Overnight study visit (up to approximately 10hrs) | |
Primary | Wake After Sleep Onset (WASO) Assessed by PSG | Total amount of minutes awake after the first sleep epoch. | Overnight study visit (up to approximately 10hrs) | |
Primary | Percentage of Time in Bed During Each Sleep Stage | Overnight study visit (up to approximately 10hrs) | ||
Primary | Position Changes Assessed by PSG | Number of times participant changed position during the sleep recording. | Overnight study visit (up to approximately 10hrs) | |
Primary | Apnea Hypopnea Index Assessed by PSG | The number of apneas or hypopneas recorded during the study per hour of sleep. | Overnight study visit (up to approximately 10hrs) | |
Primary | Heart Rate | Overnight study visit (up to approximately 10hrs) | ||
Primary | Periodic Leg Movements (PLM) During Sleep | Number of times participant had periodic leg movements during the sleep recording | Overnight study visit (up to approximately 10hrs) | |
Primary | Mean EEG Delta Spectral Power Per Second Over 90 Mins From Lights Off Between 0-360 Minutes After Lights Off | EEG data collected from the electrode in position C2 | Overnight study visit (up to approximately 10hrs) | |
Secondary | Core Body Temperature | Difference in core body temperature changes of the high and low rebound mattress toppers at sleep onset and during sleep. The core body temperature will be monitored every minute throughout the night. | Overnight study visit (up to approximately 10hrs) | |
Secondary | Visual Analog Scale of Sleep | visual analog scale of sleep was used for evaluation of subjective sleep quality. Scale ranged from 0 cm (very bad) to 10 cm (very good). | Overnight study visit (up to approximately 10hrs) | |
Secondary | Visual Analog Scale of Performance | visual analog scale of performance was used for evaluation of subjective performance quality. Scale ranged from 0 cm (very bad) to 10 cm (very good). | Overnight study visit (up to approximately 10hrs) | |
Secondary | Visual Analog Scale of Mood | visual analog scale of mood was used for evaluation of subjective mood. Scale ranged from 0 cm (very bad) to 10 cm (very good). | Overnight study visit (up to approximately 10hrs) | |
Secondary | Alliance Sleep Questionnaire (ASQ) | self-reported information related to sleep | Overnight study visit (up to approximately 10hrs) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02188498 -
Electrocardiography Data Analysis in Sleep Disorders
|
||
Completed |
NCT00990106 -
Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)
|
N/A | |
Completed |
NCT00942253 -
Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS)
|
Phase 2 | |
Completed |
NCT00163670 -
The Impact of Sleep Disorders on Motor Vehicle Accidents
|
N/A | |
Completed |
NCT00203827 -
Pediatric Sleep Questionnaire: Use for Collection of Clinical Data
|
N/A | |
Completed |
NCT00256685 -
Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause
|
Phase 3 | |
Completed |
NCT00174174 -
Provigil (Modafinil) Study by Taiwan Biotech Co.
|
N/A | |
Terminated |
NCT00750919 -
Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)
|
Phase 3 | |
Completed |
NCT03075241 -
Z-Drugs for Sleep Disorders in Alzheimer's Disease
|
Phase 3 | |
Completed |
NCT02939586 -
The Effect of Haemodialysis in Sleep Apnoea
|
N/A | |
Completed |
NCT02585609 -
Sleep Quality in Patients With Advanced Cancer
|
N/A | |
Completed |
NCT01929447 -
Evaluation of WP200 With the Unified Probe (WP200U)
|
N/A | |
Completed |
NCT01906866 -
Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities
|
Phase 3 | |
Completed |
NCT02156128 -
Subjective Memory Complaints, Objective Memory Performance and Cognitive Training
|
N/A | |
Completed |
NCT01528462 -
Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke
|
||
Completed |
NCT01220401 -
Efficacy of a Brief Nightmare Treatment for Veterans
|
N/A | |
Completed |
NCT01256983 -
Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation
|
Phase 0 | |
Not yet recruiting |
NCT00749814 -
Sleep Disturbances in Hospitalized Children
|
Phase 4 | |
Completed |
NCT00518986 -
Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression
|
Phase 4 | |
Completed |
NCT00397930 -
Yoga in Treating Sleep Disturbance in Cancer Survivors
|
Phase 2 |